This is the first multicenter study from Pakistan exploring the prevalence, clinical presentations and treatment outcomes of Multiple Myeloma patients. This retrospective study involved data collection from hospital record system of four tertiary care referral hospitals of Pakistan including all patients diagnosed as having Multiple Myeloma from January 2014 to December 2018. The demographic details, clinical presentations, laboratory findings, treatment responses, and mortalities were evaluated. The progression-free survival and overall survival were analyzed considering relapse and mortality as the end points, respectively. For the progression-free survival, the Kaplan–Meier survival analysis and the log rank test were used to compare the survival function for chemotherapy followed by autologous stem cell transplant (ASCT) as opposed to chemotherapy alone (non-ASCT). The overall survival analysis was assessed by Kaplan–Meier survival analysis. This study identified 403 Multiple Myeloma patients in five years. The median age at presentation was 55 years. Bortezomib based drug regimens were the most commonly used initial treatments (57.5%). Forty three patients received ASCT. The progression-free survival median for ASCT and non-ASCT patients were 50 months (95% CI, 42–57.9 months) and 26 months (95% CI, 21.5–30.5 months), respectively. The cumulative probability of survival rate at 60 months was 80%. This study identified 403 Multiple Myeloma patients over 5 years in four tertiary care hospitals of Pakistan. It underscores the importance of autologous stem cell transplant in Myeloma patients and advocates improving its facilities in Pakistan.

这是来自巴基斯坦的第一项探索多发性骨髓瘤患者的患病率、临床表现和治疗结果的多中心研究。这项回顾性研究涉及从巴基斯坦四家三级转诊医院的医院记录系统收集数据，包括 2014 年 1 月至 2018 年 12 月诊断为多发性骨髓瘤的所有患者。评估了人口统计细节、临床表现、实验室结果、治疗反应和死亡率. 分别以复发和死亡率为终点分析无进展生存期和总生存期。对于无进展生存期，Kaplan-Meier 生存分析和对数秩检验用于比较化疗后自体干细胞移植 (ASCT) 与单独化疗（非 ASCT）的生存函数。通过 Kaplan-Meier 生存分析评估总体生存分析。这项研究在五年内确定了 403 名多发性骨髓瘤患者。就诊时的中位年龄为 55 岁。基于硼替佐米的药物治疗方案是最常用的初始治疗 (57.5%)。43 名患者接受了 ASCT。ASCT 和非 ASCT 患者的无进展生存期中位数分别为 50 个月（95% CI，42-57.9 个月）和 26 个月（95% CI，21.5-30.5 个月）。60 个月时的累积生存概率为 80%。这项研究在巴基斯坦的四家三级医院确定了 403 名超过 5 年的多发性骨髓瘤患者。它强调了自体干细胞移植对骨髓瘤患者的重要性，并主张改善其在巴基斯坦的设施。